在精密瘤学试验中使用外部控制来评估治疗结果的框架
Derrick H W Siu1,2, Frank P Y Lin1,3,4, Doah Cho1
1National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
JCO precision oncology
|January 8, 2024
概括
本次审查提出了在精密瘤学试验中使用外部控制 (EC) 的框架,特别是在罕见子组中. 它概述了强有力的比较分析的关键步骤和考虑因素,以推动药物开发.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 临床试验 临床试验
背景情况:
- 基因组学的进步允许针对性的抗癌疗法.
- 单臂试验 (SAT) 在罕见的生物标志物定义的亚群中很常见.
- 外部控制 (EC) 提供了一种策略来补充SAT用于比较分析.
研究的目的:
- 在精密瘤学中使用EC进行前性比较分析的框架.
- 解决方法方面的挑战,并确定生物标志物定义的亚群中ECs的考虑因素.
- 为精密瘤学的证据生成和药物开发提供指导.
主要方法:
- 定义EC的目的和适用性.
- 制定透明的研究协议和统计分析计划.
- 具体考虑生物标志物状态,治疗线和队列分层.
主要成果:
- 提出了使用EC进行前性比较分析的四步框架.
- 对生物标志物定义的子群体的具体考虑是详细的.
- 讨论了利用EC的新型试验设计和统计技术.
结论:
- 拟议的框架有助于在精密瘤学中使用EC进行可靠的比较分析.
- 解决特定考虑因素可以提高EC在生物标志物定义的亚群中的有效性.
- 未来的方向旨在通过创新的试验设计和EC利用来推动证据生成和药物开发.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
129
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
129
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K
Cancer Survival Analysis
353
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
353
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Kaplan-Meier Approach
146
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
146


